| Patent application number | Description | Published |
|---|
| 20090123920 | JAK2 MUTATIONS - The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides methods and compositions useful for diagnosing neoplastic diseases including, for example, myeloproliferative diseases. The invention also provides methods and compositions useful for determining a prognosis of an individual diagnosed as having a neoplastic disease. | 05-14-2009 |
| 20090142755 | ASSAY FOR DETECTING GENETIC ABNORMALITIES IN GENOMIC NUCLEIC ACIDS - The present invention provides methods of detecting unamplifed genomic nucleic acid anchored to a solid support. The methods are useful for the detecting genetic abnormalities associated with various diseases, diagnosis, and prognosis. | 06-04-2009 |
| 20090286260 | MYELOPEROXIDASE DETECTION IN DIAGNOSIS AND PROGNOSIS OF HEMATOPOIETIC DISORDERS - The present invention relates to the diagnosis of hematopoietic disorders and to determining the prognosis of patients affected by such disorders. The methods generally comprise determining a level of myeloperoxidase in a body fluid sample from the individual and using the level as a factor for diagnosing the disorder in the mammal or as a factor for determining the prognosis of a patient diagnosed with such a disorder. Myelodysplastic syndrome, acute myeloid leukemia and chronic myeloid leukemia are exemplary disorders. Also provided are method of cancer therapy involving reducing the level of myeloperoxidase in the body fluid of the individual. | 11-19-2009 |
| 20100028930 | HEMATOPOIETIC CELL PHENOTYPING USING CIRCULATING CELL-FREE MARKERS - The present invention provides methods of classifying cluster of differentiation (CD) marker phenotype for hematopoietic cancer cells using multiple circulating cell-free CD markers in bodily fluid. In other aspects, treatment and disease progression of particular hematopoietic cancers can be monitored by measuring the levels of CD and other markers i bodily fluids of a patient. | 02-04-2010 |
| 20100063747 | Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction of Response to Therapy and Clinical Behavior, Stratification of Therapy, and Monitoring Disease in Hematologic Malignancies - The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies. | 03-11-2010 |
| 20100099084 | DETECTION OF NPM1 NUCLEIC ACID IN ACELLULAR BODY FLUIDS - The present inventions relates to methods for detecting NPM1 nucleic acid in acellular body fluid samples and determining whether the nucleic acid contains one or more mutations including insertions and deletions. The methods are useful for predicting prognosis of AML patients that have cells with mutations in the NPM1 gene. | 04-22-2010 |
| 20100112571 | COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID - The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease. | 05-06-2010 |
| 20100113470 | BCR-ABL VARIANTS - A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed. | 05-06-2010 |
| 20100124741 | METHODS FOR DETECTING IgH/BCL-1 CHROMOSOMAL TRANSLOCATION - The invention provides methods for detection of Bcl-1 nucleic acid in acellular body fluid. The methods can be used to detect the IgH/Bcl-1 translocations (11;14)(q13;q32) in acellular body fluid. The chromosomal translocation (11;14)(q13;q32) is often associated with mantle cell (centrocytic) lymphoma and occasionally in other B-cell neoplasms, notably myeloma. The invention is useful in the diagnosis of mantle cell lymphoma (MCL) and also for determining the prognosis of the disease. | 05-20-2010 |
| 20100159456 | METHODS FOR DETECTING TCR-GAMMA GENE REARRANGEMENT - The invention provides methods for detection of TCR-γ nucleic acid in acellular body fluid. The methods can be used to detect the TCR-γ gene rearrangement in acellular body fluid. The detection of TCR-γ gene rearrangement is useful in determination of clonality of T-cell population. The invention is useful in the diagnosis of lymphoproliferative disorder. | 06-24-2010 |
| 20100304390 | METHODS FOR DETECTING GENE DYSREGULATIONS - Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5′ and 3′ regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene. | 12-02-2010 |
| 20110053197 | UBIQUITIN PROTEASOME SYSTEM PROFILING AND THE USE THEREOF IN CLINICAL APPLICATIONS FOR CANCER DIAGNOSIS - Provided herein are methods for the diagnosis, prognosis, or management of neoplastic diseases, i.e. cancer, and other diseases using profiles of the ubiquitin-proteasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of cancer patients. | 03-03-2011 |
| 20110053198 | UBIQUITIN PROTEASOME SYSTEM PROFILING AND THE USE THEREOF IN CLINICAL APPLICATIONS FOR PROLIFERATIVE HEMATOLOGICAL DISORDERS - Provided herein are methods for the diagnosis, prognosis, or management of proliferative hematological disorders and other diseases using profiles of the ubiquitin-proteasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of leukemia patients. | 03-03-2011 |
| 20110053199 | UBIQUITIN PROTEASOME SYSTEM PROFILING AND THE USE THEREOF IN CLINICAL APPLICATIONS FOR CANCER DIAGNOSIS - Provided herein are methods for the diagnosis, prognosis, or management of neoplastic diseases, i.e. cancer, and other diseases using profiles of the ubiquitin-protcasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of cancer patients. | 03-03-2011 |
| 20110072889 | BCR-ABL TRUNCATION MUTATIONS - Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed. | 03-31-2011 |
| 20110076709 | Method for the Diagnosis of Leukemia Using Caspase-3 - The invention provides methods for determining the prognosis of a patient diagnosed with a leukemia, including B-cell chronic lymphocytic leukemia and acute myelogenous leukemia, by measuring the level of caspase-3 activity in a biological sample. The invention also relates to the diagnosis of leukemia, including B-cell chronic lymphocytic leukemia and acute myelogenous leukemia. | 03-31-2011 |
| 20110223607 | CIRCULATING MICRORNA AS A MARKER FOR HEPATOCELLULAR CARCINOMA - Provided herein are methods for the diagnosis, or management of liver diseases, e.g., hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids. | 09-15-2011 |
| 20110269162 | UBIQUITIN PROTEASOME SYSTEM PROFILING FOR DIAGNOSIS OF CHRONIC LIVER DISEASE - Provided herein are methods for the diagnosis, staging, prognosis, or management of liver disease, e.g. chronic liver disease, and other diseases using profiles of the ubiquitin-proteasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of patients with liver disease. | 11-03-2011 |
| 20110281268 | CIRCULATING MICRORNA AS A MARKER FOR HEPATOCELLULAR CARCINOMA - Provided herein are methods for the diagnosis, or management of liver diseases, e.g. hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids. | 11-17-2011 |
| 20120003653 | COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID - The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease. | 01-05-2012 |
| 20120009571 | TMPRSS2 FOR THE DIAGNOSIS OF PROSTATE DISEASE - Described herein are methods, compositions and kits directed to the detection the 5′ portion of TMPRSS2 mRNA for the detection and diagnosis of prostate disease including prostate cancer and benign prostatic hyperplasia. | 01-12-2012 |
| 20120145891 | Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction Of Response To Therapy And Clinical Behavior, Stratification Of Therapy, And Monitoring Disease In Hematologic Malignancies - The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies. | 06-14-2012 |
| 20120329049 | BCR-ABL1 SPLICE VARIANTS AND USES THEREOF - The present invention is based on BCR-ABL1 splice variants which result from insertion and/or truncation of the BCR-ABL1 transcript and the finding that these variants provide resistance to kinase domain inhibitors such as imatinib, nilotinib and dasatinib. | 12-27-2012 |
| 20130288236 | WT1 MUTATIONS FOR PROGNOSIS OF MYELOPROLIFERATIVE DISORDERS - The invention provides methods for determining the prognosis of a patient diagnosed with a leukemia, including B-cell chronic lymphocytic leukemia, by measuring mutations of the WT1 gene in a biological sample. The invention also relates to the diagnosis of leukemia, including B-cell chronic lymphocytic leukemia. | 10-31-2013 |
| 20130295562 | METHODS FOR DETECTING RISK OF MYELODYSPLASTIC SYNDROME BY GENOTYPIC ANALYSIS - The present invention provides methods for detecting the risk of developing leukemia using genotyping analysis, for example of a SNP located in the promoter region of EPO. The present invention also provides kits and nucleic acids for the detection of the risk genotype. | 11-07-2013 |
| 20130316341 | METHODS FOR DETECTING GENE DYSREGULATIONS - Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5′ and 3′ regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene. | 11-28-2013 |
| 20130330719 | EML4-ALK TRANSLOCATIONS IN LUNG CANCER - The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders. | 12-12-2013 |
| 20140057270 | COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID - The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferalive diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease. | 02-27-2014 |
| 20140072972 | TMPRSS2 FOR THE DIAGNOSIS OF PROSTATE DISEASE - Described herein are methods, compositions and kits directed to the detection the 5′ portion of TMPRSS2 mRNA for the detection and diagnosis of prostate disease including prostate cancer and benign prostatic hyperplasia. | 03-13-2014 |
| 20150038367 | METHODS FOR DETECTING GENE DYSREGULATIONS - Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5′ and 3′ regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene. | 02-05-2015 |
| 20150080255 | MPL MUTATIONS IN JAK2 V617F NEGATIVE PATIENTS WITH MYELOPROLIFERATIVE DISEASE - The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products. | 03-19-2015 |
